[
  {
    "ts": "2025-10-28T22:15:00+00:00",
    "headline": "Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson",
    "summary": "Levin Papantonio legal team Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A. Casaretto, finding that Johnson & Johnson’s talc-based products caused his fatal mesothelioma. The lawsuit, brought by his son, Alberto Casaretto Jr., alleged that the company’s talc was contaminated with asbestos and that Johnson & Johnson failed to warn consumers. The",
    "url": "https://finance.yahoo.com/news/levin-papantonio-announces-jury-awards-221500775.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "bbbffb46-b066-395a-a72e-f99245dbe58a",
      "content": {
        "id": "bbbffb46-b066-395a-a72e-f99245dbe58a",
        "contentType": "STORY",
        "title": "Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson",
        "description": "",
        "summary": "Levin Papantonio legal team Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A. Casaretto, finding that Johnson & Johnson’s talc-based products caused his fatal mesothelioma. The lawsuit, brought by his son, Alberto Casaretto Jr., alleged that the company’s talc was contaminated with asbestos and that Johnson & Johnson failed to warn consumers. The",
        "pubDate": "2025-10-28T22:15:00Z",
        "displayTime": "2025-10-28T22:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/22b5cf7ac83ab713071f7e11c246cebc",
          "originalWidth": 2192,
          "originalHeight": 1944,
          "caption": "Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i1TArft7tttLdP5zfMF6BA--~B/aD0xOTQ0O3c9MjE5MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/22b5cf7ac83ab713071f7e11c246cebc.cf.webp",
              "width": 2192,
              "height": 1944,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zx_xjkY0ASJ6Biy6a.M6oA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/22b5cf7ac83ab713071f7e11c246cebc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/levin-papantonio-announces-jury-awards-221500775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/levin-papantonio-announces-jury-awards-221500775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T20:14:21+00:00",
    "headline": "Is Johnson & Johnson’s Share Price Justified After Recent Surge in 2025?",
    "summary": "Trying to figure out whether to buy, sell, or hold Johnson & Johnson? You are not alone. The stock price has been on a bit of a rollercoaster lately, closing most recently at $190.3. After a dip of 1.8% this past week, J&J is still up an impressive 5.9% over the last month, 32.1% year to date, and 21.6% in the past year. That kind of track record definitely attracts attention from investors searching for stable growth, but the real question is whether the current price makes sense compared to...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-share-price-justified-201421536.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d1562170-cd27-3a63-97db-b9fa4e5e516a",
      "content": {
        "id": "d1562170-cd27-3a63-97db-b9fa4e5e516a",
        "contentType": "STORY",
        "title": "Is Johnson & Johnson’s Share Price Justified After Recent Surge in 2025?",
        "description": "",
        "summary": "Trying to figure out whether to buy, sell, or hold Johnson & Johnson? You are not alone. The stock price has been on a bit of a rollercoaster lately, closing most recently at $190.3. After a dip of 1.8% this past week, J&J is still up an impressive 5.9% over the last month, 32.1% year to date, and 21.6% in the past year. That kind of track record definitely attracts attention from investors searching for stable growth, but the real question is whether the current price makes sense compared to...",
        "pubDate": "2025-10-28T20:14:21Z",
        "displayTime": "2025-10-28T20:14:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-share-price-justified-201421536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-share-price-justified-201421536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T18:44:00+00:00",
    "headline": "Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism",
    "summary": "The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.",
    "url": "https://www.wsj.com/health/healthcare/texas-sues-kenvue-alleging-omission-of-autism-link-from-tylenol-marketing-d5ab7d50?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "6c15ee91-fb6d-3f43-a105-92d2130d3858",
      "content": {
        "id": "6c15ee91-fb6d-3f43-a105-92d2130d3858",
        "contentType": "STORY",
        "title": "Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism",
        "description": "",
        "summary": "The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.",
        "pubDate": "2025-10-28T18:44:00Z",
        "displayTime": "2025-10-28T18:44:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6c15ee91-fb6d-3f43-a105-92d2130d3858/texas-suit-accuses-tylenol.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/09a7ed14f4ec0d72ad41b6c432a63e6c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gj28O9nOErmPVWBOT3bXVA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/09a7ed14f4ec0d72ad41b6c432a63e6c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI7PDdMzMPdZ9Klc1A0XbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/09a7ed14f4ec0d72ad41b6c432a63e6c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/healthcare/texas-sues-kenvue-alleging-omission-of-autism-link-from-tylenol-marketing-d5ab7d50?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T16:26:00+00:00",
    "headline": "Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders.",
    "summary": "Texas joined the Trump administration in claiming Tylenol causes autism.  Shares of  Kenvue  fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while pregnant.  The suit also named  Johnson & Johnson  which spun off Kenvue in 2023.",
    "url": "https://www.barrons.com/articles/tylenol-sues-texas-autism-kenvue-stock-price-3524c54a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "7fc1b1d5-9df9-31b4-8920-a7c949d30c7c",
      "content": {
        "id": "7fc1b1d5-9df9-31b4-8920-a7c949d30c7c",
        "contentType": "STORY",
        "title": "Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders.",
        "description": "",
        "summary": "Texas joined the Trump administration in claiming Tylenol causes autism.  Shares of  Kenvue  fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while pregnant.  The suit also named  Johnson & Johnson  which spun off Kenvue in 2023.",
        "pubDate": "2025-10-28T16:26:00Z",
        "displayTime": "2025-10-28T16:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7fc1b1d5-9df9-31b4-8920-a7c949d30c7c/tylenol-is-tied-to-autism-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/9ea5bfc064ed5ba99949dcb5431aea00",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wN2NlmN7uU77NECJ.XN_gQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/9ea5bfc064ed5ba99949dcb5431aea00.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCrU41vJpmMHP_bfGErF4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/9ea5bfc064ed5ba99949dcb5431aea00.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/tylenol-sues-texas-autism-kenvue-stock-price-3524c54a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T16:24:08+00:00",
    "headline": "H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. The analyst supported the optimistic rating with the company’s growth potential and the stability of […]",
    "url": "https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-162408183.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f0e01cf4-7629-33f1-88bd-f7eb4b485ec6",
      "content": {
        "id": "f0e01cf4-7629-33f1-88bd-f7eb4b485ec6",
        "contentType": "STORY",
        "title": "H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90",
        "description": "",
        "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. The analyst supported the optimistic rating with the company’s growth potential and the stability of […]",
        "pubDate": "2025-10-28T16:24:08Z",
        "displayTime": "2025-10-28T16:24:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J713X2G_4n.5dZjnwBOXZw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3TpP6OHB5FXGiA99gusCDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-162408183.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-162408183.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HALO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:42:52+00:00",
    "headline": "Texas sues Kenvue and J&J, Truth Social to offer prediction markets",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (JNJ) and Kenvue (KVUE) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (DHI) topping quarterly home orders estimates, and Trump Media & Technology Group (DJT, DJTWW) offering predictions market features on Truth Social. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
    "url": "https://finance.yahoo.com/video/texas-sues-kenvue-j-j-144252078.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "ebe827c4-f03c-32c5-98aa-a29be57e5c82",
      "content": {
        "id": "ebe827c4-f03c-32c5-98aa-a29be57e5c82",
        "contentType": "VIDEO",
        "title": "Texas sues Kenvue and J&J, Truth Social to offer prediction markets",
        "description": "<p>Market Catalysts host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/julie-hyman/?.tsrc=fin-srch\">Julie Hyman</a> tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>) and Kenvue (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/KVUE\">KVUE</a>) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/DHI\">DHI</a>) topping quarterly home orders estimates, and Trump Media & Technology Group (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/DJT\">DJT</a>, <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/DJTWW\">DJTWW</a>) offering predictions market features on Truth Social.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (JNJ) and Kenvue (KVUE) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (DHI) topping quarterly home orders estimates, and Trump Media & Technology Group (DJT, DJTWW) offering predictions market features on Truth Social. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
        "pubDate": "2025-10-28T14:42:52Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-10/604a88b0-b40c-11f0-bd65-5594f342cc40",
          "originalWidth": 5800,
          "originalHeight": 3259,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4D_iWaexoJvt53jf7874zg--~B/aD0zMjU5O3c9NTgwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-10/604a88b0-b40c-11f0-bd65-5594f342cc40.cf.webp",
              "width": 5800,
              "height": 3259,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vy0GFwRGmo79jdqzxyldjQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-10/604a88b0-b40c-11f0-bd65-5594f342cc40.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/texas-sues-kenvue-j-j-144252078.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/texas-sues-kenvue-j-j-144252078.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "DHI"
            },
            {
              "symbol": "DJT"
            },
            {
              "symbol": "DJTWW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:13:45+00:00",
    "headline": "As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain",
    "summary": "Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.",
    "url": "https://247wallst.com/investing/2025/10/28/dow-jones-hits-record-top-dividend-dogs-of-the-dow-still-a-bargain/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "183ef8af-aa9a-301e-bd47-c3e262dfcad2",
      "content": {
        "id": "183ef8af-aa9a-301e-bd47-c3e262dfcad2",
        "contentType": "STORY",
        "title": "As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain",
        "description": "",
        "summary": "Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.",
        "pubDate": "2025-10-28T14:13:45Z",
        "displayTime": "2025-10-28T14:13:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8oHqLvL4LSIh_k84TF28VQ--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M2B5MfoEY0V7wX_NrqStUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/10/28/dow-jones-hits-record-top-dividend-dogs-of-the-dow-still-a-bargain/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dow-hits-record-high-yield-141345983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "VZ"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:11:53+00:00",
    "headline": "Update: Texas AG Sues Kenvue, Johnson & Johnson for Alleged Deceptive Marketing of Tylenol to Pregnant Women",
    "summary": "(Update with Kenvue's and Johnson & Johnson's responses to requests for comment from MT Newswires in",
    "url": "https://finance.yahoo.com/news/texas-ag-sues-kenvue-johnson-141153666.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "8e73b4e4-6f29-34b7-a27e-271596e46771",
      "content": {
        "id": "8e73b4e4-6f29-34b7-a27e-271596e46771",
        "contentType": "STORY",
        "title": "Update: Texas AG Sues Kenvue, Johnson & Johnson for Alleged Deceptive Marketing of Tylenol to Pregnant Women",
        "description": "",
        "summary": "(Update with Kenvue's and Johnson & Johnson's responses to requests for comment from MT Newswires in",
        "pubDate": "2025-10-28T14:11:53Z",
        "displayTime": "2025-10-28T14:11:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/texas-ag-sues-kenvue-johnson-141153666.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/texas-ag-sues-kenvue-johnson-141153666.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:00:00+00:00",
    "headline": "2 Dividend Stocks to Double Up on Right Now",
    "summary": "They are about as safe as dividends can get.",
    "url": "https://www.fool.com/investing/2025/10/28/2-dividend-stocks-to-double-up-on-right-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "bdf82f10-ba23-3fba-8a8f-195380cd78ff",
      "content": {
        "id": "bdf82f10-ba23-3fba-8a8f-195380cd78ff",
        "contentType": "STORY",
        "title": "2 Dividend Stocks to Double Up on Right Now",
        "description": "",
        "summary": "They are about as safe as dividends can get.",
        "pubDate": "2025-10-28T14:00:00Z",
        "displayTime": "2025-10-28T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/bbf4d9d4d1144c177db91acf539bd359",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person drinking bottled drink with a straw. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h9zRCFnvh5D_6_tGMfrU4g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/bbf4d9d4d1144c177db91acf539bd359.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BycNWrCYDGRT3DOt38Tlkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bbf4d9d4d1144c177db91acf539bd359.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/28/2-dividend-stocks-to-double-up-on-right-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-dividend-stocks-double-now-140000505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:00:00+00:00",
    "headline": "ISRG Rides on da Vinci 5 Momentum: Can This Growth Sustain?",
    "summary": "Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.",
    "url": "https://finance.yahoo.com/news/isrg-rides-da-vinci-5-140000860.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d8b668ce-f015-3fd0-bbb8-21fce196dd7d",
      "content": {
        "id": "d8b668ce-f015-3fd0-bbb8-21fce196dd7d",
        "contentType": "STORY",
        "title": "ISRG Rides on da Vinci 5 Momentum: Can This Growth Sustain?",
        "description": "",
        "summary": "Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.",
        "pubDate": "2025-10-28T14:00:00Z",
        "displayTime": "2025-10-28T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ly2eKWIt2DGVNvSZ_c1.OQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jcy0r8Ec0Arq0Msc4P7F2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/isrg-rides-da-vinci-5-140000860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/isrg-rides-da-vinci-5-140000860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ISRG"
            },
            {
              "symbol": "STXS"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T12:48:00+00:00",
    "headline": "Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?",
    "summary": "ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.",
    "url": "https://finance.yahoo.com/news/buy-abbvie-stock-ahead-q3-124800552.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "355db9c2-b574-338c-9dbe-ae9acea2fdf3",
      "content": {
        "id": "355db9c2-b574-338c-9dbe-ae9acea2fdf3",
        "contentType": "STORY",
        "title": "Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?",
        "description": "",
        "summary": "ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.",
        "pubDate": "2025-10-28T12:48:00Z",
        "displayTime": "2025-10-28T12:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-abbvie-stock-ahead-q3-124800552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-abbvie-stock-ahead-q3-124800552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]